RNA-lipid vaccine approach for glioblastoma in newly diagnosed patients
Official title: A phase I study of RNA-lipid particle vaccines for newly-diagnosed glioblastoma, IND19304 08/21/2020
Funded at University of Florida · NIH-11420160 · Data updated 2026-11-12
A new RNA-lipid particle vaccine is being tested to help the body’s own immune system fight glioblastoma in people who have just been diagnosed.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Florida NIH-funded |
| Lab location | 1 site (Gainesville, United States) |
| Project start | August 15, 2022 |
| Project end | July 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $1,245,669 |
| NIH project number | 5R01FD007268-04 |
| Project ID | NIH-11420160 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults newly diagnosed with glioblastoma who are eligible for the vaccine study.
✕Less likely to help
Patients whose tumors do not respond to the vaccine or who experience intolerable side effects may not benefit.
What this research studies
This research aims to use tumor RNA packaged in multi-lamellar RNA-lipid particles to prompt the immune system to attack glioblastoma cells. The approach is designed to activate dendritic cells and stimulate both innate and adaptive immune responses against glioma antigens. The goal is to achieve robust anti-tumor immunity with potential long-term survival benefits, building on prior safety data in animals and a canine glioma trial. The study is conducted at the University of Florida under the leadership of Dr. Elias Sayour and has progressed through preclinical work and regulatory steps.
Why it matters
Potential benefit: If successful, patients with glioblastoma could experience improved tumor control and longer survival through a powerful vaccine-based therapy.
How similar studies have gone: Preclinical and canine studies have shown safety and immunologic activity, with encouraging signals of effectiveness in disease models.
Where this research is happening
-
University of Florida
Gainesville, United States Active
Researchers
- Principal investigator: Sayour, Elias — University of Florida
- Study coordinator: Sayour, Elias
Related research
Other NIH-funded projects on the same topics.
-
Small molecules to block Slit2/ROBO in glioblastoma
A study to test small molecule drugs that block Slit2/ROBO signals to help treat glioblastoma in patients.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
Small-molecule and biologic treatments for glioblastoma using targeted brain delivery
A new approach aims to use FPS-ZM1 to shrink brain swelling and support immunotherapy for glioblastoma, potentially helping patients recover after surgery.
-
Targeted therapies for glioblastoma in adults and kids
A large NIH program is exploring new brain cancer therapies, including drugs that reach the brain and work against glioblastoma in both children and adults.
-
6-thio-2'-deoxyguanosine for glioblastoma: a new approach to target tumors before surgery
A trial tests a novel drug given before glioblastoma surgery to see how it behaves in the body and within the tumor, and to learn how it affects cancer cells and the immune environment.
-
CD38-Driven Changes in Brain Tumor Metabolism and Immunity in Glioblastoma
A patient-facing look at how scientists plan to study how glioblastoma grows by changing its metabolism and dampening the immune response, with potential targets to help treatment in the future.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.